Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
1.
J Vector Borne Dis ; 55(1): 42-46, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29916447

RESUMEN

BACKGROUND & OBJECTIVES: Leishmania parasites are sensitive to very low temperature. Cryotherapy is considered as an alternative to the existing pentavalent antimonials, for local treatment of cutaneous leishmaniasis (CL). Normally, liquid nitrogen (N2) at a temperature of -196 °C, is used in cryotherapy of CL, but it's efficacy is not consistent. Recently, few studies have also reported the use of carbon dioxide (CO2) slush at -78.5 °C in CL cryotherapy. This study was aimed to evaluate the effectiveness of N2 vs CO2 cryotherapy for CL treatment in mice. Methods: In total, 21 BALB/c mice were infected with Leishmania major strain [MRHO/IR/74/ER]. Samples were divided into three groups based on the intervention provided-Solid CO2 cryotherapy, liquid N2 cryotherapy and control group; with seven mice randomly assigned to each group. Control group received no intervention, and in the other two groups cryotherapy was used every two weeks for maximum of three months. Follow up examinations were scheduled at the time of cryotherapy, during which the size of each lesion was measured. For three mice in each study group, the spleen parasite DNA load was quantified using real-time PCR. RESULTS: After treatment, the liquid N2 cryotherapy showed significant reduction in size of the lesions (p = 0.029) as compared to the solid CO2 cryotherapy and control group. Also, Leishmania DNA load in spleen was significantly lower in the mice receiving liquid N2 cryotherapy (p <0.001). INTERPRETATION & CONCLUSION: Liquid N2 cryotherapy is superior to CO2 cryotherapy, and it can be an effective method for controlling L. major infection. Further investigations are essential to find optimal number of treatment sessions and time intervals.


Asunto(s)
Dióxido de Carbono/uso terapéutico , Crioterapia/métodos , Leishmania major , Leishmaniasis Cutánea/terapia , Nitrógeno/uso terapéutico , Administración Cutánea , Animales , Dióxido de Carbono/administración & dosificación , Femenino , Leishmania major/genética , Leishmania major/aislamiento & purificación , Leishmania major/fisiología , Leishmaniasis Cutánea/parasitología , Ratones , Ratones Endogámicos BALB C , Nitrógeno/administración & dosificación , Carga de Parásitos , Distribución Aleatoria , Bazo/parasitología
2.
Dermatol Ther ; 28(3): 140-6, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-25847678

RESUMEN

A simple efficacious topical treatment for cutaneous leishmaniasis (CL) is still an unresolved challenge. This study aimed to evaluate the efficacy of the topical use of thioxolone plus benzoxonium chloride (Thio-Ben) tincture in combination with cryotherapy in comparison with intralesional meglumine antimoniate (Glucantime) along with cryotherapy in treating anthroponotic CL (ACL). The study was conducted in Leishmaniasis Center in Dadbin Health Care Clinic, Kerman, Iran. Sixty-four CL lesions were randomly assigned to receive Thio-Ben plus cryotherapy (TC) (n = 32) or Glucantime plus cryotherapy (GC) (n = 32). Thio-Ben was used topically every other day and Glucantime was used intralesionally once a week for a maximum of 3 months. In both study groups, cryotherapy was administered using liquid nitrogen once every 2 weeks. Of 64 recruited lesions, 47 lesions completed the study protocol. Twenty lesions (91%) in TC group and 23 lesions (92%) in GC group showed complete cure. TC group showed faster clinical response. Pain, hypersensitivity reaction, dizziness, and nausea were only seen in GC group. This study showed that the topical use of Thio-Ben combined with cryotherapy has a good efficacy in treating ACL with the benefit that Thio-Ben has more patient compliance and less side effects than intralesional Glucantime.


Asunto(s)
Antiinfecciosos Locales/administración & dosificación , Compuestos de Benzalconio/administración & dosificación , Crioterapia , Lactonas/administración & dosificación , Leishmaniasis Cutánea/terapia , Adolescente , Adulto , Antiprotozoarios/administración & dosificación , Niño , Preescolar , Terapia Combinada , Esquema de Medicación , Combinación de Medicamentos , Femenino , Humanos , Irán , Leishmaniasis Cutánea/diagnóstico , Leishmaniasis Cutánea/parasitología , Masculino , Meglumina/administración & dosificación , Antimoniato de Meglumina , Datos de Secuencia Molecular , Compuestos Organometálicos/administración & dosificación , Cooperación del Paciente , Recurrencia , Inducción de Remisión , Método Simple Ciego , Factores de Tiempo , Resultado del Tratamiento , Adulto Joven
3.
Int J Dermatol ; 60(11): e440-e448, 2021 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-33615455

RESUMEN

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic, painful, and severely debilitating inflammatory disease that affects apocrine gland-bearing skin. There is no universal consensus on the management of hidradenitis suppurativa (HS). Current available guidelines are from western countries, which may be of limited use in other parts of the world. In this study, we aim to identify trends in the management of HS in the Middle East (ME) and its differences with the West. METHODS: A systematic literature review was performed to identify all studies in HS management performed by experts in the ME from database inception to June 2020 using PubMed, EMBASE, and Cochrane Library databases. Only original articles published in English language were included. Guidelines from western countries were used for comparison. RESULTS: Fifty-four eligible studies comprising 7649 HS patients from the ME region and nine guidelines from the West were included. No established guidelines were found for the management of HS in the ME. Sex ratio of HS patients in the ME is different in that men reported to be affected at a higher rate than in the West. Different antibiotic regimens were recommended in the ME, and the experts in the ME tend to be more procedure intensive than experts in the West. CONCLUSIONS: Establishing a guideline for HS management in the ME is recommended to address unique considerations in the countries in this region.


Asunto(s)
Hidradenitis Supurativa , Antibacterianos/uso terapéutico , Consenso , Hidradenitis Supurativa/diagnóstico , Hidradenitis Supurativa/tratamiento farmacológico , Hidradenitis Supurativa/epidemiología , Humanos , Masculino , Medio Oriente/epidemiología , Piel
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA